Literature DB >> 20010576

Medicare formulary coverage for top-selling biologics.

Su-Ying Liang, Jennifer S Haas, Kathryn A Phillips.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20010576      PMCID： PMC2845541          DOI： 10.1038/nbt1209-1082

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  Specialty pharmacy cost management strategies of private health care payers.

Authors:  Debbie Stern; Debi Reissman
Journal:  J Manag Care Pharm       Date:  2006 Nov-Dec

2.  Insurers' strategies for managing the use and cost of biopharmaceuticals.

Authors:  James C Robinson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

3.  Health plans' strategies for managing outpatient specialty pharmaceuticals.

Authors:  C Daniel Mullins; Danielle Chauncey Lavallee; Françoise G Pradel; Andrea R DeVries; Nadine Caputo
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

4.  Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006.

Authors:  Jennifer Bowman; Amy Rousseau; David Silk; Catherine Harrison
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Coverage and prior authorization of psychotropic drugs under Medicare Part D.

Authors:  Haiden A Huskamp; David G Stevenson; Julie M Donohue; Joseph P Newhouse; Nancy L Keating
Journal:  Psychiatr Serv       Date:  2007-03       Impact factor: 3.084

6.  Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.

Authors:  Chien-Wen Tseng; Carol M Mangione; Robert H Brook; Emmett Keeler; R Adams Dudley
Journal:  JAMA       Date:  2007-06-20       Impact factor: 56.272

7.  Biologics and Benefit Design: What's New For '06?

Authors:  Katherine T Adams
Journal:  Biotechnol Healthc       Date:  2006-02
  7 in total
  4 in total

1.  Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Authors:  Jinoos Yazdany; R Adams Dudley; Randi Chen; Grace A Lin; Chien-Wen Tseng
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

2.  Variability in drug formularies and implications in decision support.

Authors:  Matthew J Stephens; John T Finnell; Linas Simonaitis; J Marc Overhage
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

Review 3.  A review of approaches for the management of specialty pharmaceuticals in the United States.

Authors:  Bijal Nitin Patel; Patricia R Audet
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

4.  Improving Access to Cancer Treatments: The Role of Biosimilars.

Authors:  Rakesh Chopra; Gilberto Lopes
Journal:  J Glob Oncol       Date:  2017-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.